2014 Q1 Form 10-K Financial Statement
#000114420414017092 Filed on March 21, 2014
Income Statement
| Concept | 2014 Q1 | 2013 Q4 | 2013 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $550.0K | $110.0K | $490.0K |
| YoY Change | 223.53% | -26.67% | -55.05% |
| % of Gross Profit | |||
| Research & Development | $160.0K | $240.0K | $879.9K |
| YoY Change | -5.88% | 84.62% | -13.07% |
| % of Gross Profit | |||
| Depreciation & Amortization | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| % of Gross Profit | |||
| Operating Expenses | $720.0K | $360.0K | $1.375M |
| YoY Change | 118.18% | 28.57% | -34.71% |
| Operating Profit | -$1.375M | ||
| YoY Change | -34.71% | ||
| Interest Expense | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| % of Operating Profit | |||
| Other Income/Expense, Net | -$210.0K | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Pretax Income | -$930.0K | -$360.0K | -$1.370M |
| YoY Change | 181.82% | 28.57% | -61.73% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$930.0K | -$360.0K | -$1.375M |
| YoY Change | 181.82% | 28.57% | -61.59% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$134.2K | -$51.95K | -$197.7K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 41.58M shares | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2014 Q1 | 2013 Q4 | 2013 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $120.0K | $480.0K | $480.0K |
| YoY Change | -91.3% | -71.08% | -71.08% |
| Cash & Equivalents | |||
| Short-Term Investments | $10.00K | $10.00K | $10.00K |
| Other Short-Term Assets | $70.00K | $70.00K | $70.00K |
| YoY Change | -30.0% | -22.22% | -22.22% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $190.0K | $558.0K | $560.0K |
| YoY Change | -87.16% | -68.17% | -68.0% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | |||
| YoY Change | |||
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | |||
| YoY Change | |||
| Total Long-Term Assets | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| TOTAL ASSETS | |||
| Total Short-Term Assets | $190.0K | $558.0K | $560.0K |
| Total Long-Term Assets | $0.00 | $0.00 | $0.00 |
| Total Assets | $190.0K | $558.0K | $560.0K |
| YoY Change | -87.16% | -68.17% | -68.0% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $80.00K | $110.0K | $110.0K |
| YoY Change | 14.29% | 37.5% | 37.5% |
| Accrued Expenses | |||
| YoY Change | |||
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $280.0K | $321.8K | $320.0K |
| YoY Change | 3.7% | 23.21% | 23.08% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $280.0K | $321.8K | $320.0K |
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $280.0K | $320.0K | $320.0K |
| YoY Change | 3.7% | 23.08% | 23.08% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | |||
| YoY Change | |||
| Common Stock | $13.19M | ||
| YoY Change | 0.91% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$100.0K | $236.3K | $240.0K |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $190.0K | $558.0K | $560.0K |
| YoY Change | -87.16% | -68.17% | -68.0% |
Cashflow Statement
| Concept | 2014 Q1 | 2013 Q4 | 2013 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$930.0K | -$360.0K | -$1.375M |
| YoY Change | 181.82% | 28.57% | -61.59% |
| Depreciation, Depletion And Amortization | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cash From Operating Activities | -$360.0K | -$320.0K | -$1.180M |
| YoY Change | 28.57% | 39.13% | -2.13% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | $0.00 | |
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Cash From Investing Activities | $0.00 | $0.00 | -$1.00 |
| YoY Change | -100.0% | ||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $0.00 | ||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 0.000 | 0.000 | $0.00 |
| YoY Change | -100.0% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -360.0K | -320.0K | -$1.180M |
| Cash From Investing Activities | 0.000 | 0.000 | -$1.00 |
| Cash From Financing Activities | 0.000 | 0.000 | $0.00 |
| Net Change In Cash | -360.0K | -320.0K | -$1.180M |
| YoY Change | 28.57% | 39.13% | -171.92% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$360.0K | -$320.0K | -$1.180M |
| Capital Expenditures | $0.00 | $0.00 | |
| Free Cash Flow | -$320.0K | -$1.180M | |
| YoY Change | 39.13% | -2.13% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2012Q4 | lixt |
Warrants Outstanding Weighted Average Exercise Price
WarrantsOutstandingWeightedAverageExercisePrice
|
0.667 | |
| CY2013Q4 | lixt |
Warrants Outstanding Weighted Average Exercise Price
WarrantsOutstandingWeightedAverageExercisePrice
|
0.667 | |
| CY2012Q4 | lixt |
Warrants Exercisable Weighted Average Exercise Price
WarrantsExercisableWeightedAverageExercisePrice
|
0.672 | |
| CY2013Q4 | lixt |
Warrants Exercisable Weighted Average Exercise Price
WarrantsExercisableWeightedAverageExercisePrice
|
0.672 | |
| CY2013 | lixt |
Warrants Outstanding Weighted Average Exercise Price Average Remaining Contractual Life
WarrantsOutstandingWeightedAverageExercisePriceAverageRemainingContractualLife
|
P8M1D | |
| CY2013 | lixt |
Warrants Exercisable Weighted Average Exercise Price Average Remaining Contractual Life
WarrantsExercisableWeightedAverageExercisePriceAverageRemainingContractualLife
|
P5M1D | |
| CY2006Q2 | lixt |
Common Stock Issued To Founders
CommonStockIssuedToFounders
|
19021786 | shares |
| CY2005Q4 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1500 | USD |
| CY2005Q4 | lixt |
Common Stock Issued To Founders Prior Share Exchange Agreement
CommonStockIssuedToFoundersPriorShareExchangeAgreement
|
1500 | shares |
| CY2006Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
25000832 | shares |
| CY2012 | lixt |
Warrants Exercised Cashless Basis Number
WarrantsExercisedCashlessBasisNumber
|
273752 | shares |
| CY2013 | lixt |
Warrants Expired Weighted Average Exercise Price
WarrantsExpiredWeightedAverageExercisePrice
|
0 | |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
236266 | USD |
| CY2013 | lixt |
Warrants Issued
WarrantsIssued
|
0 | shares |
| CY2012 | lixt |
Warrants Exercised
WarrantsExercised
|
6355752 | shares |
| CY2013 | lixt |
Warrants Exercised
WarrantsExercised
|
0 | shares |
| CY2012 | lixt |
Warrants Expired
WarrantsExpired
|
270000 | shares |
| CY2013 | lixt |
Warrants Expired
WarrantsExpired
|
0 | shares |
| CY2012Q4 | lixt |
Warrants Outstanding
WarrantsOutstanding
|
6828800 | shares |
| CY2013Q4 | lixt |
Warrants Outstanding
WarrantsOutstanding
|
6828800 | shares |
| CY2012Q4 | lixt |
Warrants Exercisable
WarrantsExercisable
|
6659840 | shares |
| CY2013Q4 | lixt |
Warrants Exercisable
WarrantsExercisable
|
6659840 | shares |
| CY2012Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1753010 | USD |
| CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
558040 | USD |
| CY2011Q4 | lixt |
Warrants Outstanding Weighted Average Exercise Price
WarrantsOutstandingWeightedAverageExercisePrice
|
0.607 | |
| CY2006Q2 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
92717 | USD |
| CY2012 | lixt |
Warrants Issued Weighted Average Exercise Price
WarrantsIssuedWeightedAverageExercisePrice
|
0 | |
| CY2013Q2 | lixt |
Estimated Cost Of Clinical Trial Lab
EstimatedCostOfClinicalTrialLab
|
2000000 | USD |
| CY2013 | lixt |
Warrants Issued Weighted Average Exercise Price
WarrantsIssuedWeightedAverageExercisePrice
|
0 | |
| CY2013 | lixt |
Cost Of Clinical Trial Lab
CostOfClinicalTrialLab
|
278721 | USD |
| CY2012 | lixt |
Warrants Exercised Weighted Average Exercise Price
WarrantsExercisedWeightedAverageExercisePrice
|
0.535 | |
| CY2013 | lixt |
Warrants Exercised Weighted Average Exercise Price
WarrantsExercisedWeightedAverageExercisePrice
|
0 | |
| CY2013Q4 | lixt |
Cash And Money Market Funds
CashAndMoneyMarketFunds
|
481154 | USD |
| CY2012 | lixt |
Warrants Expired Weighted Average Exercise Price
WarrantsExpiredWeightedAverageExercisePrice
|
0.844 | |
| CY2012 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
10578800 | shares |
| CY2013 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2013 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9978800 | shares |
| CY2012Q4 | us-gaap |
Cash
Cash
|
1655122 | USD |
| CY2013Q4 | us-gaap |
Cash
Cash
|
475019 | USD |
| CY2012Q4 | us-gaap |
Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
|
6134 | USD |
| CY2013Q4 | us-gaap |
Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
|
6135 | USD |
| CY2012Q4 | lixt |
Advances On Research And Development Contract Services
AdvancesOnResearchAndDevelopmentContractServices
|
51575 | USD |
| CY2013Q4 | lixt |
Advances On Research And Development Contract Services
AdvancesOnResearchAndDevelopmentContractServices
|
33880 | USD |
| CY2012Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
40179 | USD |
| CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
43006 | USD |
| CY2012Q4 | us-gaap |
Assets Current
AssetsCurrent
|
1753010 | USD |
| CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
558040 | USD |
| CY2012Q4 | us-gaap |
Assets
Assets
|
1753010 | USD |
| CY2013Q4 | us-gaap |
Assets
Assets
|
558040 | USD |
| CY2012Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
80416 | USD |
| CY2013Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
107774 | USD |
| CY2012Q4 | lixt |
Research And Development Contract Liabilities
ResearchAndDevelopmentContractLiabilities
|
14019 | USD |
| CY2013Q4 | lixt |
Research And Development Contract Liabilities
ResearchAndDevelopmentContractLiabilities
|
47283 | USD |
| CY2012Q4 | lixt |
Liquidated Damages Payable Under Registration Rights Agreement
LiquidatedDamagesPayableUnderRegistrationRightsAgreement
|
74000 | USD |
| CY2013Q4 | lixt |
Liquidated Damages Payable Under Registration Rights Agreement
LiquidatedDamagesPayableUnderRegistrationRightsAgreement
|
74000 | USD |
| CY2012Q4 | us-gaap |
Due To Officers Or Stockholders Current
DueToOfficersOrStockholdersCurrent
|
92717 | USD |
| CY2013Q4 | us-gaap |
Due To Officers Or Stockholders Current
DueToOfficersOrStockholdersCurrent
|
92717 | USD |
| CY2012Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
261152 | USD |
| CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
321774 | USD |
| CY2012Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2013Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2012Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2013Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2012Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
4158 | USD |
| CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
4158 | USD |
| CY2012Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
13064831 | USD |
| CY2013Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
13184081 | USD |
| CY2012Q4 | us-gaap |
Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
|
11577131 | USD |
| CY2013Q4 | us-gaap |
Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
|
12951973 | USD |
| CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1491858 | USD |
| CY2013 | lixt |
Deferred Setup And Organization Costs Amortization Period
DeferredSetupAndOrganizationCostsAmortizationPeriod
|
P180M | |
| CY2013 | lixt |
Expiration Date
ExpirationDate
|
P20Y | |
| CY2011Q4 | lixt |
Warrants Outstanding
WarrantsOutstanding
|
13454552 | shares |
| CY2012 | lixt |
Warrants Issued
WarrantsIssued
|
0 | shares |
| CY2012 | lixt |
Common Stock Issued Cashless Exercise Of Warrants Number
CommonStockIssuedCashlessExerciseOfWarrantsNumber
|
141955 | shares |
| CY2012 | lixt |
Warrants Extension Stock Agreed For Issuance Number
WarrantsExtensionStockAgreedForIssuanceNumber
|
273752 | shares |
| CY2009 | lixt |
Advances Under Equity Financing During Period
AdvancesUnderEquityFinancingDuringPeriod
|
1200000 | USD |
| CY2010Q1 | lixt |
Proceeds From Advances Under Equity Financing
ProceedsFromAdvancesUnderEquityFinancing
|
587500 | USD |
| CY2006Q4 | lixt |
Liquidated Damages Payable Under Registration Rights Agreement
LiquidatedDamagesPayableUnderRegistrationRightsAgreement
|
74000 | USD |
| CY2012 | lixt |
Cash Basis Warrants Exercise Price Reduction Percentage
CashBasisWarrantsExercisePriceReductionPercentage
|
0.25 | pure |
| lixt |
Maximum Proceeds Expected From Issuance Of Warrants
MaximumProceedsExpectedFromIssuanceOfWarrants
|
3000000 | USD | |
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
2468250 | USD | |
| lixt |
Fair Value Of Warrant Discount
FairValueOfWarrantDiscount
|
334024 | USD | |
| CY2012 | lixt |
Stock Warrants Exercisable Fair Market Value
StockWarrantsExercisableFairMarketValue
|
0.83 | |
| CY2013Q4 | lixt |
Stock Warrants Outstanding
StockWarrantsOutstanding
|
168960 | shares |
| CY2012 | lixt |
Cashless Basis Warrants Exercise Price Increased Percentage
CashlessBasisWarrantsExercisePriceIncreasedPercentage
|
0.2 | pure |
| CY2012 | lixt |
Cashless Exercise Price
CashlessExercisePrice
|
0.333 | |
| CY2012 | lixt |
Increased Cashless Exercise Price
IncreasedCashlessExercisePrice
|
0.3996 | |
| CY2012 | lixt |
Number Of Common Stock To Be Issued Upon Conversion Of Warrants
NumberOfCommonStockToBeIssuedUponConversionOfWarrants
|
5080000 | shares |
| CY2012 | lixt |
Stock Options And Warrants Exercisable Fair Market Value
StockOptionsAndWarrantsExercisableFairMarketValue
|
0.25 | |
| CY2013 | lixt |
Stock Options And Warrants Exercisable Fair Market Value
StockOptionsAndWarrantsExercisableFairMarketValue
|
0.13 | |
| CY2012Q4 | us-gaap |
Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
|
6134 | USD |
| CY2013Q4 | us-gaap |
Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
|
6135 | USD |
| CY2011Q1 | lixt |
Officers Compensation Approved Per Month
OfficersCompensationApprovedPerMonth
|
5000 | USD |
| CY2011Q1 | lixt |
Officers Compensation Approved Per Month Effective Date Of Adoption
OfficersCompensationApprovedPerMonthEffectiveDateOfAdoption
|
2011-03-15 | |
| CY2012 | us-gaap |
Officers Compensation
OfficersCompensation
|
60000 | USD |
| CY2013 | us-gaap |
Officers Compensation
OfficersCompensation
|
60000 | USD |
| us-gaap |
Officers Compensation
OfficersCompensation
|
167500 | USD | |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3150000 | shares |
| CY2012Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
41583097 | shares |
| CY2012 | lixt |
Stock Based Compensation Expense Relating To Directors Officers And Other Related Parties
StockBasedCompensationExpenseRelatingToDirectorsOfficersAndOtherRelatedParties
|
1017004 | USD |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
3512500 | shares |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
3000000 | shares |
| CY2013Q4 | us-gaap |
Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
|
40000 | USD |
| CY2013 | lixt |
Stock Options Vested
StockOptionsVested
|
150000 | shares |
| CY2013 | lixt |
Stock Based Compensation Expense Relating To Directors Officers And Other Related Parties
StockBasedCompensationExpenseRelatingToDirectorsOfficersAndOtherRelatedParties
|
119250 | USD |
| lixt |
Stock Based Compensation Expense Relating To Directors Officers And Other Related Parties
StockBasedCompensationExpenseRelatingToDirectorsOfficersAndOtherRelatedParties
|
3598461 | USD | |
| CY2012Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2013Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2012Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2013Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2012Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2013Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2012Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2013Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2012Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2012Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
41583097 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
41583097 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
41583097 | shares |
| CY2011Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3250000 | shares |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
1200000 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
100000 | shares |
| CY2012 | lixt |
Share Based Compensation Share Based Payment Award Options Exercised
ShareBasedCompensationShareBasedPaymentAwardOptionsExercised
|
100000 | shares |
| CY2013 | lixt |
Share Based Compensation Share Based Payment Award Options Exercised
ShareBasedCompensationShareBasedPaymentAwardOptionsExercised
|
0 | shares |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
600000 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
700000 | shares |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3750000 | shares |
| CY2011Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
0.884 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0.796 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0.130 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0.333 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
0.889 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
1.045 | |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
0.870 | |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
0.818 | |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
0.876 | |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
0.843 | |
| CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P2Y7M13D | |
| CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P2Y6M7D | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
200000 | shares | |
| CY2011Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
200000 | shares |
| CY2011Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
0.98 | |
| CY2009Q1 | lixt |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested
|
25000 | shares |
| CY2011Q2 | lixt |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested
|
25000 | shares |
| CY2011Q2 | lixt |
Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValue
|
49000 | USD |
| CY2008Q1 | lixt |
Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value Charged To Operations
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueChargedToOperations
|
75000 | USD |
| lixt |
Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value Charged To Operations
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueChargedToOperations
|
41334 | USD | |
| CY2009Q4 | lixt |
Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value Charged To Operations
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueChargedToOperations
|
375000 | USD |
| CY2013Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
100000 | shares |
| CY2011Q3 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
100000 | shares |
| CY2008 | lixt |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Ratably
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedRatably
|
50000 | shares |
| CY2007Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
33333 | USD |
| CY2007Q2 | lixt |
Maximum Shares For Granting Of Awards
MaximumSharesForGrantingOfAwards
|
2500000 | shares |
| CY2011Q4 | lixt |
Payments To Fund Cooperative Research And Development
PaymentsToFundCooperativeResearchAndDevelopment
|
25000 | USD |
| CY2013Q4 | lixt |
Research And Development Contracts Contractual Obligation
ResearchAndDevelopmentContractsContractualObligation
|
40385 | USD |
| CY2013 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
494959 | USD |
| CY2013Q4 | lixt |
Work Order Agreement
WorkOrderAgreement
|
1746463 | USD |
| CY2013Q4 | lixt |
Patent License Agreement
PatentLicenseAgreement
|
150000 | USD |
| CY2013Q4 | us-gaap |
Due To Officers Or Stockholders Current And Noncurrent
DueToOfficersOrStockholdersCurrentAndNoncurrent
|
92717 | USD |
| CY2013Q4 | lixt |
Principal Cash Obligations And Commitments
PrincipalCashObligationsAndCommitments
|
2119565 | USD |
| CY2006Q1 | lixt |
Cooperative Research And Development Project Commitments Amount
CooperativeResearchAndDevelopmentProjectCommitmentsAmount
|
200000 | USD |
| CY2009Q3 | lixt |
Cooperative Research And Development Project Commitments Amount
CooperativeResearchAndDevelopmentProjectCommitmentsAmount
|
100000 | USD |
| CY2009Q3 | lixt |
Cooperative Research And Development Project Commitments Amount
CooperativeResearchAndDevelopmentProjectCommitmentsAmount
|
200000 | USD |
| CY2006Q3 | lixt |
Cooperative Research Commitments Due Current
CooperativeResearchCommitmentsDueCurrent
|
200000 | USD |
| CY2012Q1 | lixt |
Payments To Fund Cooperative Research And Development
PaymentsToFundCooperativeResearchAndDevelopment
|
25000 | USD |
| CY2009Q1 | lixt |
Payments To Fund Cooperative Research And Development
PaymentsToFundCooperativeResearchAndDevelopment
|
50000 | USD |
| CY2007Q2 | lixt |
Payments To Fund Cooperative Research And Development
PaymentsToFundCooperativeResearchAndDevelopment
|
200000 | USD |
| CY2008Q3 | lixt |
Payments To Fund Cooperative Research And Development
PaymentsToFundCooperativeResearchAndDevelopment
|
50000 | USD |
| CY2008Q4 | lixt |
Payments To Fund Cooperative Research And Development
PaymentsToFundCooperativeResearchAndDevelopment
|
50000 | USD |
| CY2010Q4 | lixt |
Payments To Fund Cooperative Research And Development
PaymentsToFundCooperativeResearchAndDevelopment
|
50000 | USD |
| CY2008Q3 | lixt |
National Institute Of Health Patent License Agreement Terms
NationalInstituteOfHealthPatentLicenseAgreementTerms
|
The PLA provided for an initial payment of $25,000 to the NIH within 60 days of September 19, 2008, and for a minimum annual royalty of $30,000 on January 1 of each calendar year following the year in which the CRADA is terminated. | |
| CY2008Q4 | lixt |
Payments To National Institute Of Health Patent License Agreement Initial Payment
PaymentsToNationalInstituteOfHealthPatentLicenseAgreementInitialPayment
|
25000 | USD |
| CY2013Q4 | lixt |
Principal Cash Obligations And Commitments Current
PrincipalCashObligationsAndCommitmentsCurrent
|
213000 | USD |
| CY2012 | lixt |
Charges To Operations
ChargesToOperations
|
24500 | USD |
| CY2013 | lixt |
Charges To Operations
ChargesToOperations
|
7275 | USD |
| CY2012 | us-gaap |
Revenues
Revenues
|
0 | USD |
| CY2013 | us-gaap |
Revenues
Revenues
|
0 | USD |
| us-gaap |
Revenues
Revenues
|
0 | USD | |
| CY2012 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1093614 | USD |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5727899 | USD | |
| CY2012 | us-gaap |
Depreciation Nonproduction
DepreciationNonproduction
|
0 | USD |
| CY2013 | us-gaap |
Depreciation Nonproduction
DepreciationNonproduction
|
0 | USD |
| us-gaap |
Depreciation Nonproduction
DepreciationNonproduction
|
1909 | USD | |
| CY2012 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1012144 | USD |
| CY2013 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
879886 | USD |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5449678 | USD | |
| CY2012 | lixt |
Reverse Merger Costs
ReverseMergerCosts
|
0 | USD |
| CY2013 | lixt |
Reverse Merger Costs
ReverseMergerCosts
|
0 | USD |
| lixt |
Reverse Merger Costs
ReverseMergerCosts
|
50000 | USD | |
| CY2012 | us-gaap |
Operating Expenses
OperatingExpenses
|
2105758 | USD |
| CY2013 | us-gaap |
Operating Expenses
OperatingExpenses
|
1374845 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
11229486 | USD | |
| CY2012 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2105758 | USD |
| CY2013 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1374845 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-11229486 | USD | |
| CY2012 | us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
8 | USD |
| CY2013 | us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
3 | USD |
| us-gaap |
Investment Income Nonoperating
InvestmentIncomeNonoperating
|
27437 | USD | |
| CY2012 | us-gaap |
Interest Expense
InterestExpense
|
0 | USD |
| CY2013 | us-gaap |
Interest Expense
InterestExpense
|
0 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
2469 | USD | |
| CY2012 | lixt |
Fair Value Of Warrant Extension
FairValueOfWarrantExtension
|
1139592 | USD |
| CY2013 | lixt |
Fair Value Of Warrant Extension
FairValueOfWarrantExtension
|
0 | USD |
| lixt |
Fair Value Of Warrant Extension
FairValueOfWarrantExtension
|
1339431 | USD | |
| CY2012 | lixt |
Fair Value Of Warrant Discount
FairValueOfWarrantDiscount
|
334024 | USD |
| CY2013 | lixt |
Fair Value Of Warrant Discount
FairValueOfWarrantDiscount
|
0 | USD |
| lixt |
Fair Value Of Warrant Discount
FairValueOfWarrantDiscount
|
334024 | USD | |
| CY2012 | lixt |
Liquidated Damages Under Registration Rights Agreement
LiquidatedDamagesUnderRegistrationRightsAgreement
|
0 | USD |
| CY2013 | lixt |
Liquidated Damages Under Registration Rights Agreement
LiquidatedDamagesUnderRegistrationRightsAgreement
|
0 | USD |
| lixt |
Liquidated Damages Under Registration Rights Agreement
LiquidatedDamagesUnderRegistrationRightsAgreement
|
74000 | USD | |
| CY2013 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1374842 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-12951973 | USD | |
| CY2012 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.09 | |
| CY2013 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.03 | |
| CY2012 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
38985832 | shares |
| CY2013 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
41583097 | shares |
| CY2005Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
0 | USD |
| lixt |
Common Stock Issued To Founders Value
CommonStockIssuedToFoundersValue
|
1500 | USD | |
| CY2006 | us-gaap |
Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
|
62500 | USD |
| CY2006 | lixt |
Shares Issued In Private Placement Net Of Offering Costs
SharesIssuedInPrivatePlacementNetOfOfferingCosts
|
969372 | USD |
| CY2007 | lixt |
Shares Issued In Private Placement Net Of Offering Costs
SharesIssuedInPrivatePlacementNetOfOfferingCosts
|
531320 | USD |
| CY2009 | lixt |
Shares Issued In Private Placement Net Of Offering Costs
SharesIssuedInPrivatePlacementNetOfOfferingCosts
|
1097050 | USD |
| CY2010 | lixt |
Shares Issued In Private Placement Net Of Offering Costs
SharesIssuedInPrivatePlacementNetOfOfferingCosts
|
1087500 | USD |
| CY2011 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
5000 | USD |
| CY2012 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3579366 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
33333 | USD |
| CY2012 | lixt |
Warrants Issued During Period Value Stock Warrants Exercised
WarrantsIssuedDuringPeriodValueStockWarrantsExercised
|
2468250 | USD |
| CY2006 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
97400 | USD |
| CY2007 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
890694 | USD |
| CY2008 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
357987 | USD |
| CY2009 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
745980 | USD |
| CY2010 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
160712 | USD |
| CY2011 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
204898 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
723554 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
119250 | USD |
| CY2007 | lixt |
Shares Issued During Period Value Stock Based Research And Development Costs
SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts
|
50836 | USD |
| CY2008 | lixt |
Shares Issued During Period Value Stock Based Research And Development Costs
SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts
|
213061 | USD |
| CY2009 | lixt |
Shares Issued During Period Value Stock Based Research And Development Costs
SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts
|
132933 | USD |
| CY2010 | lixt |
Shares Issued During Period Value Stock Based Research And Development Costs
SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts
|
67222 | USD |
| CY2011 | lixt |
Shares Issued During Period Value Stock Based Research And Development Costs
SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts
|
982 | USD |
| CY2012 | lixt |
Shares Issued During Period Value Stock Based Research And Development Costs
SharesIssuedDuringPeriodValueStockBasedResearchAndDevelopmentCosts
|
293450 | USD |
| CY2012 | lixt |
Adjustments To Additional Paid In Capital Fair Value Of Warrant Discount
AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrantDiscount
|
334024 | USD |
| CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
|
199839 | USD |
| CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
|
1139592 | USD |
| CY2006 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-562084 | USD |
| CY2007 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1648488 | USD |
| CY2008 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1271522 | USD |
| CY2009 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1551333 | USD |
| CY2010 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-880250 | USD |
| CY2011 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2067964 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-16124 | USD | |
| CY2006Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
552564 | USD |
| CY2007Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
376926 | USD |
| CY2008Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-323548 | USD |
| CY2009Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1301082 | USD |
| CY2010Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1736266 | USD |
| CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
79021 | USD |
| CY2005Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-14624 | USD |
| CY2012 | us-gaap |
Depreciation
Depreciation
|
0 | USD |
| CY2013 | us-gaap |
Depreciation
Depreciation
|
0 | USD |
| us-gaap |
Depreciation
Depreciation
|
1909 | USD | |
| CY2012 | lixt |
General And Administrative Stock Based Expenses
GeneralAndAdministrativeStockBasedExpenses
|
723554 | USD |
| CY2013 | lixt |
General And Administrative Stock Based Expenses
GeneralAndAdministrativeStockBasedExpenses
|
119125 | USD |
| lixt |
General And Administrative Stock Based Expenses
GeneralAndAdministrativeStockBasedExpenses
|
3300100 | USD | |
| CY2012 | lixt |
Research And Development Stock Based Expenses
ResearchAndDevelopmentStockBasedExpenses
|
293450 | USD |
| CY2013 | lixt |
Research And Development Stock Based Expenses
ResearchAndDevelopmentStockBasedExpenses
|
125 | USD |
| lixt |
Research And Development Stock Based Expenses
ResearchAndDevelopmentStockBasedExpenses
|
758609 | USD | |
| CY2012 | lixt |
Increase Decrease In Advances On Research And Development Contract Services
IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
|
22592 | USD |
| CY2013 | lixt |
Increase Decrease In Advances On Research And Development Contract Services
IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
|
-17695 | USD |
| lixt |
Increase Decrease In Advances On Research And Development Contract Services
IncreaseDecreaseInAdvancesOnResearchAndDevelopmentContractServices
|
33880 | USD | |
| CY2012 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
4825 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
344995 | USD |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1500 | USD | |
| CY2013 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2827 | USD |
| CY2012 | lixt |
Increase Decrease In Liquidated Damages Payable Under Registration Rights Agreement
IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement
|
0 | USD |
| CY2013 | lixt |
Increase Decrease In Liquidated Damages Payable Under Registration Rights Agreement
IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement
|
0 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1 | USD |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-8044 | USD | |
| lixt |
Increase Decrease In Liquidated Damages Payable Under Registration Rights Agreement
IncreaseDecreaseInLiquidatedDamagesPayableUnderRegistrationRightsAgreement
|
74000 | USD | |
| CY2012 | lixt |
Increase Decrease In Research And Development Contract Liabilities
IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
|
-60669 | USD |
| CY2013 | lixt |
Increase Decrease In Research And Development Contract Liabilities
IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
|
33264 | USD |
| lixt |
Increase Decrease In Research And Development Contract Liabilities
IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
|
47283 | USD | |
| CY2012 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
33333 | USD |
| CY2013 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | USD |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
43006 | USD | |
| CY2012 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-28925 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
27358 | USD |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
107774 | USD | |
| CY2012 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1205757 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1180102 | USD |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-7065729 | USD | |
| CY2012 | lixt |
Payments To Acquire Money Market Funds
PaymentsToAcquireMoneyMarketFunds
|
-344995 | USD |
| CY2013 | lixt |
Payments To Acquire Money Market Funds
PaymentsToAcquireMoneyMarketFunds
|
1 | USD |
| lixt |
Payments To Acquire Money Market Funds
PaymentsToAcquireMoneyMarketFunds
|
6135 | USD | |
| CY2012 | us-gaap |
Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
|
0 | USD |
| CY2013 | us-gaap |
Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
|
0 | USD |
| us-gaap |
Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
|
1909 | USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
38333 | USD | |
| CY2012 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
2468250 | USD |
| CY2013 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
0 | USD |
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
2468250 | USD | |
| CY2012 | lixt |
Proceeds From Sale Of Common Stock To Consulting Firm
ProceedsFromSaleOfCommonStockToConsultingFirm
|
0 | USD |
| CY2013 | lixt |
Proceeds From Sale Of Common Stock To Consulting Firm
ProceedsFromSaleOfCommonStockToConsultingFirm
|
0 | USD |
| lixt |
Proceeds From Sale Of Common Stock To Consulting Firm
ProceedsFromSaleOfCommonStockToConsultingFirm
|
250 | USD | |
| CY2012 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | USD |
| CY2013 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | USD |
| CY2005Q3 | us-gaap |
Cash
Cash
|
0 | USD |
| CY2012 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| CY2012 | lixt |
Proceeds From Issuance Of Notes Payable To Consultants
ProceedsFromIssuanceOfNotesPayableToConsultants
|
0 | USD |
| CY2013 | lixt |
Proceeds From Issuance Of Notes Payable To Consultants
ProceedsFromIssuanceOfNotesPayableToConsultants
|
0 | USD |
| lixt |
Proceeds From Issuance Of Notes Payable To Consultants
ProceedsFromIssuanceOfNotesPayableToConsultants
|
200000 | USD | |
| CY2012 | lixt |
Repayments Of Notes Payable To Consultant
RepaymentsOfNotesPayableToConsultant
|
0 | USD |
| CY2013 | lixt |
Repayments Of Notes Payable To Consultant
RepaymentsOfNotesPayableToConsultant
|
0 | USD |
| lixt |
Repayments Of Notes Payable To Consultant
RepaymentsOfNotesPayableToConsultant
|
200000 | USD | |
| CY2012 | us-gaap |
Cash Acquired From Acquisition
CashAcquiredFromAcquisition
|
0 | USD |
| CY2013 | us-gaap |
Cash Acquired From Acquisition
CashAcquiredFromAcquisition
|
0 | USD |
| us-gaap |
Cash Acquired From Acquisition
CashAcquiredFromAcquisition
|
62500 | USD | |
| CY2012 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
0 | USD |
| CY2013 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
0 | USD |
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
5331389 | USD | |
| CY2012 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | USD |
| CY2013 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | USD |
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
446147 | USD | |
| CY2012 | us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
0 | USD |
| CY2013 | us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
0 | USD |
| us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
92717 | USD | |
| CY2012 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
2501583 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | USD |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
7548792 | USD | |
| CY2012 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
1640821 | USD |
| CY2013 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-1180103 | USD |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
475019 | USD | |
| CY2011Q4 | us-gaap |
Cash
Cash
|
14301 | USD |
| CY2013 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| CY2013 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2013 | |
| CY2013 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2013Q2 | dei |
Entity Public Float
EntityPublicFloat
|
3179000 | USD |
| us-gaap |
Interest Paid
InterestPaid
|
2469 | USD | |
| CY2012 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2013 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD | |
| CY2012 | lixt |
Decrease In Advances Under Equity Financing
DecreaseInAdvancesUnderEquityFinancing
|
0 | USD |
| CY2013 | lixt |
Decrease In Advances Under Equity Financing
DecreaseInAdvancesUnderEquityFinancing
|
0 | USD |
| lixt |
Decrease In Advances Under Equity Financing
DecreaseInAdvancesUnderEquityFinancing
|
1200000 | USD | |
| CY2012 | lixt |
Cashless Exercise Of Warrants And Options Aggregate Exercise Price
CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice
|
109391 | USD |
| CY2013 | lixt |
Cashless Exercise Of Warrants And Options Aggregate Exercise Price
CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice
|
0 | USD |
| lixt |
Cashless Exercise Of Warrants And Options Aggregate Exercise Price
CashlessExerciseOfWarrantsAndOptionsAggregateExercisePrice
|
193598 | USD | |
| CY2013 | dei |
Document Type
DocumentType
|
10-K | |
| CY2013 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2013 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2013-12-31 | |
| CY2013 | dei |
Trading Symbol
TradingSymbol
|
LIXT | |
| CY2014Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
41583097 | shares |
| CY2013 | dei |
Entity Registrant Name
EntityRegistrantName
|
LIXTE BIOTECHNOLOGY HOLDINGS, INC. | |
| CY2013 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001335105 | |
| CY2013 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2013 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2013 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2013 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2013 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2012Q4 | lixt |
Deferred Tax Assets Preliminary Costs
DeferredTaxAssetsPreliminaryCosts
|
63000 | USD |
| CY2013Q4 | lixt |
Deferred Tax Assets Preliminary Costs
DeferredTaxAssetsPreliminaryCosts
|
56000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
68000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
95000 | USD |
| CY2012Q4 | lixt |
Deferred Tax Assets Contingent Liability
DeferredTaxAssetsContingentLiability
|
31000 | USD |
| CY2013Q4 | lixt |
Deferred Tax Assets Contingent Liability
DeferredTaxAssetsContingentLiability
|
31000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
2421000 | USD |
| CY2012 | us-gaap |
Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
|
724204 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
2939000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
2583000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
3121000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
2583000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
3121000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2012 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
-0.340 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
-0.340 | pure |
| CY2012 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
0.086 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
0.029 | pure |
| CY2012 | lixt |
Effective Income Tax Rate Reconciliation Non Deductible Expense Warrant Extension Cost
EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseWarrantExtensionCost
|
0.108 | pure |
| CY2013 | lixt |
Effective Income Tax Rate Reconciliation Non Deductible Expense Warrant Extension Cost
EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseWarrantExtensionCost
|
0 | pure |
| CY2012 | lixt |
Effective Income Tax Rate Reconciliation Reduction To Operating Loss
EffectiveIncomeTaxRateReconciliationReductionToOperatingLoss
|
0.032 | pure |
| CY2013 | lixt |
Effective Income Tax Rate Reconciliation Reduction To Operating Loss
EffectiveIncomeTaxRateReconciliationReductionToOperatingLoss
|
0 | pure |
| CY2012 | lixt |
Effective Income Tax Rate Reconciliation Adjustment To Deferred Tax Asset
EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset
|
-0.020 | pure |
| CY2013 | lixt |
Effective Income Tax Rate Reconciliation Adjustment To Deferred Tax Asset
EffectiveIncomeTaxRateReconciliationAdjustmentToDeferredTaxAsset
|
-0.013 | pure |
| CY2012 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.134 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.324 | pure |
| CY2012 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.0 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.0 | pure |
| CY2013Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
7099000 | USD |
| CY2013 | lixt |
Operating Loss Carry Forwards Expiration Period
OperatingLossCarryForwardsExpirationPeriod
|
P2032Y | |
| CY2013 | lixt |
Exercise Price Reduction Percentage
ExercisePriceReductionPercentage
|
0.5 | pure |
| CY2012Q4 | lixt |
Research And Development Contract Liabilities To Related Parties
ResearchAndDevelopmentContractLiabilitiesToRelatedParties
|
9679 | USD |
| CY2013Q4 | lixt |
Research And Development Contract Liabilities To Related Parties
ResearchAndDevelopmentContractLiabilitiesToRelatedParties
|
34398 | USD |
| CY2013 | us-gaap |
Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
|
115768 | USD |
| us-gaap |
Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
|
2763909 | USD | |
| CY2012 | lixt |
Related Parties Research And Development Costs
RelatedPartiesResearchAndDevelopmentCosts
|
185536 | USD |
| CY2013 | lixt |
Related Parties Research And Development Costs
RelatedPartiesResearchAndDevelopmentCosts
|
304102 | USD |
| lixt |
Related Parties Research And Development Costs
RelatedPartiesResearchAndDevelopmentCosts
|
548272 | USD | |
| CY2013 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Concentration of Risk</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman'"><font style="FONT-FAMILY:times new roman,times,serif"><font style="FONT-SIZE: 10pt">The Company periodically contracts with directors, including companies controlled by or associated with directors, to provide consulting services related to the Company’s research and development and clinical trial activities. Agreements for these services can be for a specific time period (typically one year) or for a specific project or task, and can include both cash and non-cash compensation.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> The only such contract that represents 10% or more of general and administrative or research and development costs is described below.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman'"><font style="FONT-SIZE: 10pt;FONT-FAMILY:times new roman,times,serif"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman'"><font style="FONT-SIZE: 10pt;FONT-FAMILY:times new roman,times,serif">On September 21, 2012, the Company entered into a work order agreement with Theradex, the CRO responsible for the clinical development of the Company’s lead compound, LB-100, to manage and administer the Phase 1 clinical trial of LB-100. Theradex is an international CRO that provides professional services for the clinical research and development of pharmaceutical compounds. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, is being carried out by nationally recognized comprehensive cancer centers, and is estimated to be completed within the next 12 to 21 months (sometime between March and December 2015). The Phase 1 clinical trial is expected to cost a total of approximately $2,000,000, with such payments expected to be divided approximately evenly between payments to Theradex for services rendered and payments for pass-through costs for the clinical center’s laboratory costs and investigator costs. Total costs charged to operations for services paid to Theradex pursuant to this arrangement, which were first incurred in 2013, were $278,721 for the year ended December 31, 2013, or approximately 32% of research and development costs for the year ended December 31, 2013. <font style="BACKGROUND-COLOR: transparent"><font style="BACKGROUND-IMAGE: none; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-REPEAT: repeat; BACKGROUND-POSITION: 0% 0%"> The costs charged to operations for amounts paid to Theradex for services relating to the Phase 1 clinical trial of LB-100 are expected to represent a larger percentage of total research and development costs during the fiscal years ending December 31, 2014 and 2015</font>.</font> Costs pursuant to this agreement are included in research and development costs in the Company's consolidated statements of operations. On May 2, 2011, Dr. Robert B. Royds, the founder, Chairman of the Board and Medical Director of Theradex, was appointed to the Company’s Board of Directors. Dr. Royds died on March 23, 2013. The death of Dr. Royds is not expected to have any impact on the management and administration of the Phase 1 clinical trial.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> </div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">In addition to the above described agreement with Theradex, the Company has also from time to time engaged Theradex to assist the Company in bringing LB-100 through the FDA approval process and to provide other services. Total fees charged to operations for services paid to Theradex pursuant to such engagements were $14,964 and $163,661 for the years ended December 31, 2013 and 2012, respectively, or approximately 2% and 16% of research and development costs for the years ended December 31, 2013 and 2012, respectively, and are included in research and development costs in the Company's consolidated statements of operations.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2013Q4 | lixt |
Consulting Agreement
ConsultingAgreement
|
16000 | USD |
| CY2012 | lixt |
Clinical Research And Development Cost Percentage
ClinicalResearchAndDevelopmentCostPercentage
|
0.16 | pure |
| CY2013 | lixt |
Clinical Research And Development Cost Percentage
ClinicalResearchAndDevelopmentCostPercentage
|
0.32 | pure |
| CY2012 | lixt |
Fees For Services Total
FeesForServicesTotal
|
163661 | USD |
| CY2013 | lixt |
Fees For Services Total
FeesForServicesTotal
|
14964 | USD |
